Jinyinqingre Oral Liquid alleviates LPS-induced acute lung injury by inhibiting the NF-κB/NLRP3/GSDMD pathway.
10.1016/S1875-5364(23)60397-8
- Author:
Shuhui WANG
1
;
Pan LEI
2
,
3
;
Ying FENG
4
;
Mingzhu JIANG
1
;
Zegan LIU
1
;
Ting SHEN
1
;
Shinan MA
4
;
Libo WANG
1
;
Xingrong GUO
5
;
Shiming DU
6
Author Information
1. School of Pharmaceutical Sciences, Hubei Key Laboratory of Wudang Local Chinese Medicine Research, Taihe Hospital, Hubei University of Medicine, Shiyan 442000, China.
2. School of Pharmaceutical Sciences, Hubei Key Laboratory of Wudang Local Chinese Medicine Research, Taihe Hospital, Hubei University of Medicine, Shiyan 442000, China
3. Hubei provincial Clinical Research Center for Umbilical Cord Blood Hematopoietic Stem Cells, Taihe Hospital, Hubei University of Medicine, Shiyan 442000, Hubei, China.
4. Department of Neurosurgery, Hubei Key Laboratory of Embryonic Stem Cell Research, Taihe Hospital, Hubei University of Medicine, Shiyan 442000, China.
5. Department of Neurosurgery, Hubei Key Laboratory of Embryonic Stem Cell Research, Taihe Hospital, Hubei University of Medicine, Shiyan 442000, China. Electronic address: gxrdl@hbmu.edu.cn.
6. School of Pharmaceutical Sciences, Hubei Key Laboratory of Wudang Local Chinese Medicine Research, Taihe Hospital, Hubei University of Medicine, Shiyan 442000, China. Electronic address: dushiming@taihehospital.com.
- Publication Type:Journal Article
- Keywords:
Acute lung injury;
Inflammation;
Jinyinqingre oral liquid;
Lipopolysaccharide;
NF-κB/NLRP3/GSDMD pathway
- MeSH:
Humans;
NF-kappa B/metabolism*;
Lipopolysaccharides/metabolism*;
NLR Family, Pyrin Domain-Containing 3 Protein/metabolism*;
Acute Lung Injury/metabolism*;
Lung;
Phosphate-Binding Proteins/therapeutic use*;
Pore Forming Cytotoxic Proteins/therapeutic use*
- From:
Chinese Journal of Natural Medicines (English Ed.)
2023;21(6):423-435
- CountryChina
- Language:English
-
Abstract:
Acute lung injury (ALI) is a prevalent and severe clinical condition characterized by inflammatory damage to the lung endothelial and epithelial barriers, resulting in high incidence and mortality rates. Currently, there is a lack of safe and effective drugs for the treatment of ALI. In a previous clinical study, we observed that Jinyinqingre oral liquid (JYQR), a Traditional Chinese Medicine formulation prepared by the Taihe Hospital, Affiliated Hospital of Hubei University of Medicine, exhibited notable efficacy in treating inflammation-related hepatitis and cholecystitis in clinical settings. However, the potential role of JYQR in ALI/acute respiratory distress syndrome (ARDS) and its anti-inflammatory mechanism remains unexplored. Thus, the present study aimed to investigate the therapeutic effects and underlying molecular mechanisms of JYQR in ALI using a mouse model of lipopolysaccharide (LPS)-induced ALI and an in vitro RAW264.7 cell model. JYQR yielded substantial improvements in LPS-induced histological alterations in lung tissues. Additionally, JYQR administration led to a noteworthy reduction in total protein levels within the BALF, a decrease in MPAP, and attenuation of pleural thickness. These findings collectively highlight the remarkable efficacy of JYQR in mitigating the deleterious effects of LPS-induced ALI. Mechanistic investigations revealed that JYQR pretreatment significantly inhibited NF-κB activation and downregulated the expressions of the downstream proteins, namely NLRP3 and GSDMD, as well as proinflammatory cytokine levels in mice and RAW2647 cells. Consequently, JYQR alleviated LPS-induced ALI by inhibiting the NF-κB/NLRP3/GSDMD pathway. JYQR exerts a protective effect against LPS-induced ALI in mice, and its mechanism of action involves the downregulation of the NF-κB/NLRP3/GSDMD inflammatory pathway.
